Equities

Pharmacielo Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PCLO:CVE

Pharmacielo Ltd

Actions
  • Price (CAD)0.07
  • Today's Change0.00 / 0.00%
  • Shares traded4.00k
  • 1 Year change-12.50%
  • Beta0.5530
Data delayed at least 15 minutes, as of Feb 13 2026 20:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PharmaCielo Ltd. is a Canada-based global company with a focus on ethical and sustainable cultivation, processing and supplying of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis products to large channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Company’s all-natural cannabis into standardized, medicinal-grade dried cannabis flower, cannabis oil extracts and cannabis-related products sold in bulk to pharmaceutical companies and medicinal cannabis distributors globally. In Colombia, PharmaCielo Colombia is a fully licensed cultivator, producer, and distributor of both TetraHydroCannabinol and Cannabidiol medical cannabis. Ubiquo is a knowledge management and medical consultation system. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate.

  • Revenue in CAD (TTM)2.83m
  • Net income in CAD-6.42m
  • Incorporated2017
  • Employees268.00
  • Location
    Pharmacielo Ltd82 Richmond Street EastTORONTO M5C 1P1CanadaCAN
  • Phone+1 (416) 315-8741
  • Fax+1 (416) 315-8741
  • Websitehttps://www.pharmacielo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kane Biotech Inc574.87k-1.95m7.26m--------12.64-0.0114-0.02140.0034-0.00470.1731.302.42---58.59-80.66-192.03---16.6044.47-338.70-257.960.7172-10.811.53--1,296.754.2130.71---1.53--
Cytophage Technologies Ltd0.00-4.57m11.17m----8.72-----0.0816-0.08160.000.01890.00-------98.03---117.55-------------59.470.5422-------69.62------
Pharmacielo Ltd2.83m-6.42m13.15m268.00------4.66-0.0356-0.03560.0156-0.07950.19941.714.10---45.28------3.13---227.15--0.0907-3.016.18--------------
Simply Solventless Concentrates Ltd30.71m4.17m17.90m192.008.790.56053.070.5830.01760.01760.26430.27650.7251.117.89159,949.409.84--13.15--28.99--13.57--0.7405-0.59810.3241--120.93---599.34------
Data as of Feb 13 2026. Currency figures normalised to Pharmacielo Ltd's reporting currency: Canadian Dollar CAD

Institutional shareholders

0.18%Per cent of shares held by top holders
HolderShares% Held
AdvisorShares Investments LLCas of 31 Dec 2025333.62k0.18%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.